Daxor (NASDAQ:DXR – Get Free Report) and Embecta (NASDAQ:EMBC – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.
Dividends
Daxor pays an annual dividend of $0.03 per share and has a dividend yield of 0.4%. Embecta pays an annual dividend of $0.60 per share and has a dividend yield of 2.9%. Embecta pays out 44.4% of its earnings in the form of a dividend.
Volatility & Risk
Daxor has a beta of -0.51, meaning that its share price is 151% less volatile than the S&P 500. Comparatively, Embecta has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Daxor | N/A | N/A | N/A |
Embecta | 6.97% | -18.54% | 11.43% |
Earnings & Valuation
This table compares Daxor and Embecta”s top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Daxor | $2.61 million | 15.41 | N/A | N/A | N/A |
Embecta | $1.12 billion | 1.06 | $78.30 million | $1.35 | 15.10 |
Embecta has higher revenue and earnings than Daxor.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Daxor and Embecta, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Daxor | 0 | 0 | 1 | 0 | 3.00 |
Embecta | 0 | 1 | 1 | 0 | 2.50 |
Daxor currently has a consensus target price of $24.75, indicating a potential upside of 198.19%. Embecta has a consensus target price of $23.00, indicating a potential upside of 12.80%. Given Daxor’s stronger consensus rating and higher probable upside, analysts clearly believe Daxor is more favorable than Embecta.
Institutional & Insider Ownership
1.3% of Daxor shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 59.0% of Daxor shares are held by company insiders. Comparatively, 0.3% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
About Daxor
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.
About Embecta
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.